A multifunctional supramolecular vesicle based on complex of cystamine dihydrochloride capped pillar[5]arene and galactose derivative for targeted drug delivery

Yuchao Lu1,2,,*
Chenxi Hou1,8
Jingli Ren1
Kui Yang1
Yincheng Chang1
Yuxin Pei1
Hai Dong1
Zhichao Pei1

1Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry and Pharmacy, Northwest A&F University, Yangling, Shaanxi 712100, People’s Republic of China; 2Analysis Center of College of Science & Technology, Hebei Agricultural University, Huanghua, Hebei 061100, People’s Republic of China; 3School of Chemistry & Chemical Engineering, Huazhong University of Science & Technology, Wuhan, Hubei 430074, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Hai Dong
School of Chemistry & Chemical Engineering, Huazhong University of Science & Technology, Wuhan, Hubei 430074, People’s Republic of China
Tel +86 278 779 3243
Fax +86 278 779 3242
Email hdong@mail.hust.edu.cn

Zhichao Pei
Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry and Pharmacy, Northwest A&F University, Yangling, Shaanxi 712100, People’s Republic of China
Tel +86 298 709 1196
Fax +86 298 709 3769
Email peizc@nwafu.edu.cn

Background: Supramolecular vesicles are a novel class of nanocarriers that have great potential in biomedicine.

Methods: A multifunctional supramolecular vesicle (CAAP5G) based on the complex of CAAP5 and galactose derivative (G) assembled via host-guest interaction was constructed.

Results: Using Human embryonic kidney T (293T) cells as experimental models, the cytotoxic effects of CAAP5G was investigated to 0–50 µmol/L for 24 h. Notably, the CAAP5G vesicles revealed low-toxicity to 293T cells. Simultaneously, we have evaluated doxorubicin hydrochloride (DOX)-loaded CAAP5G vesicles anticancer efficiency, where DOX-loaded CAAP5G vesicles and free DOX incubated with Human hepatocellular carcinoma cancer cell (HpeG2 cells) and 293T cells for 24 h, 48 h, 72 h. It turned out that CAAP5G vesicles encapsulated anticancer drug (DOX) could decrease DOX side-effect on 293T cells and increase DOX anticancer efficiency. More importantly, the cysteamine as an adjuvant chemotherapy drug was released from CAAP5G vesicles in HepG2 cells where a higher GSH concentration exists. The adjuvant chemotherapy efficiency was evaluated, where free DOX and DOX-loaded CAAP5G vesicles incubated with DOX-resistance HepG2 cells (HepG2-ADR cells) for 24, 48, 72 h, respectively.

Conclusion: The results revealed that the DOX encapsulated by CAAP5G vesicles could enhance the cytotoxicity of DOX and provide insights for designing advanced nano-carriers toward adjuvant chemotherapies.

Keywords: supramolecular vesicles, cysteamine, responsive, adjuvant chemotherapies, targeted drug delivery

Introduction

Drug resistance of cancer cells and side effects to normal cells are major problems in cancer chemotherapy.1–3 Nano-carriers (NC) are one of the most widely explored drug carriers in biomedicine with its distinctive properties.4,5 Especially, targeted and stimuli-responsive nano-carriers (TSNC) can target cancer cells,6–9 achieve a rapid release in the specific tumor microenvironments, enhance cytotoxicity and reduce adverse effect via new concepts or strategies based on nanotechnology.10–13 Vesicles have been one of the most popular TSNC due to their unique cavity that have the potential to encapsulate and controllably release drugs in response to
Among them, supramolecular vesicles from amphiphilic supra-molecules via host-guest complexation, especially with targeted and stimuli-responsive units, are very important in the application of biotechnology and biomedicine. Therefore, the construction of targeted and stimuli-responsive vesicles from multifunctional amphiphilic supra-molecule based on host-guest interaction between macrocyclic host molecule and guest molecule is of particular interest and importance in the progress of stimuli-responsive systems for targeted drug delivery.

Pillar[n]arenes, a new class of macrocyclic host molecule, have received much attention in supramolecular chemistry. Due to their intrinsic symmetrical and rigid structure, accessible modification and excellent properties in host-guest chemistry, pillar[n]arenes have been widely used to construct various interesting supramolecular vesicles for TSNC. For example, our group developed two types of multifunctional supramolecular vesicles, by using ferrocene or tryptophan capped pillar[5]arene, which exhibited good responsiveness and significantly enhanced the cytotoxicity of DOX.

The cystamine dihydrochloride (CA), an important pharmaceutical intermediate that contained a disulfide bond (sensitive to GSH) and amino groups (sensitive to pH), was investigated. Most importantly, CA can produce the drug cysteamine in the presence of GSH for adjuvant chemotherapy. Previous studies showed that the cysteamine not only inhibited the formation of gastric and mammary tumors that were induced chemically or after irradiation, and also enhanced the cytotoxicity of DOX. To the best of our knowledge, CA modified pillar[5]arene for constructing a dual-responsive amphiphilic host molecule have not yet been reported. We hypothesized that synthesis of CA capping pillararene would not only lead to a GSH-pH dual responsive amphiphilic host molecule, but also the cysteamine produced by the CA could enhance the cytotoxicity of DOX for adjuvant chemotherapy.

In this study, a CA-capped pillar[5]arene (CAAP5) amphiphilic host molecule was first synthesized, and thereafter the multifunctional supramolecular vesicles (CAAP5G) constructed from CAAP5 and a galactose derivative guest molecule (G) based on host-guest interaction for targeted drug nanocarriers (Scheme 1), where the galactose residue on one end of G can act as the targeting ligand to asialoglycoprotein receptor (ASGP-R) overexpressing HepG2 cells via carbohydrate-protein interactions.

Material and methods

Instrumentation and materials

All chemical reagents were of analytical reagent grade and used without further purification unless specified. Doxorubicin hydrochloride was purchased from Sangon Biotech. NMR spectra were recorded on a Bruker 500 MHz Spectrometer, with working frequencies of 500 MHz for 1H and 125 MHz for 13C nuclei, respectively. Scanning electron microscope (SEM) images were obtained using an S-4800 instrument (Hitachi Ltd.) with an accelerating voltage of 10.0 kV. Dynamic light scattering (DLS) measurements were performed on a Delsa Nano system (Beckman Coulter, U.S.A.). Water surface tension was recorded with a BZY-3B surface tension measurer (China). An AXIMA-CFR™ plus MALDI-TOF Mass Spectrometer (Kratos, UK) was used for mass analysis. UV-Vis spectra were recorded with a Shimadzu 1750 UV-Visible spectrophotometer (Japan) at 298 K. HepG2 cells and HepG2-ADR cells were obtained from the Type Culture Collection of the Chinese Academy of Science (Shanghai, China). 293T cells were obtained from the KeyGEN BioTECH Co. (Nanjing, China). Cell culture was carried out in an incubator with a humidified atmosphere of 5% CO₂ at 37 °C.

Methods

The preparation and characterization of the vesicles

2.46 mg (0.5 µmol) of CAAP5 was dissolved in H₂O (0.5 mL) and stirred for 5 min. The solution was mixed 0.5 mL G (1 mM). The final mixture was ultrasonicated for 30 min, then left to stand for 6 h to obtain the vesicles of CAAP5G, which were characterized by SEM, DLS, and TEM, respectively.

DOX loading and release of CAAP5G vesicles

2.46 mg (0.5 µmol) of CAAP5 was dissolved in H₂O (0.5 mL) and stirred for 5 min. To the solution were mixed 0.5 mL G (1 µmol) and 0.58 mg DOX (1 µmol). The mixture was ultrasonicated for 30 min and left to stand for 6 h, then subjected to dialysis (molecular weight cutoff 8,000–14,000) in distilled water. DOX-loaded vesicles were obtained when no DOX detected in the water outside the dialysis tube.

The DOX release from DOX-loaded CAAP5G was studied at different pH buffer solution, with or without
GSH (10 mM). 1 mL of DOX-loaded vesicles in a dialysis bag was added into 10 mL of corresponding release medium at room temperature. Within specified time intervals, 0.1 mL of the release medium was taken out for measuring the DOX released with an Epoch microplate spectrophotometer (Biotek).

**Cell culture and cell viability**

HepG2 cells and HepG2-ADR cells were cultured in RPMI 1640 containing 1% penicillin-streptomycin, 10% FBS, in a humidified atmosphere (5% CO₂) at 37 °C. 293T cells were cultured in DMEM medium containing 1% penicillin-streptomycin, 10% FBS, in a humidified atmosphere (5% CO₂) at
37 °C. The relative cytotoxicity of unloaded vesicles, DOX and DOX-loaded vesicles were evaluated in vitro by MTT assay, respectively. MTT assay procedures refer to our previous work.44

Results and discussion

To acquire CAAP5, azido-pillar[5]arene H5 and alkynyl cystamine derivative H4 were synthesized according to a published procedure, respectively.45,46 The CAAP5 can be synthesized through Cu-catalyzed azido-alkynyl click reaction. The synthetic details and characterization of CAAP5 and G can be found in the Supporting Information (Schemes S1–S3, Figures S1–S11).

The host-guest interaction of CAAP5 and G was investigated in D2O via the 1H NMR spectroscopy. The upfield chemical shifts of the pyridine protons (H1-3) of G were observed due to the shielding effect of the electron-rich cavities of CAAP5 toward G (see in Figure S12). This result was consistent with that published,21,32,33 demonstrating the pyridine moiety of G has been successfully included into the hydrophobic cavity of CAAP5.

To construct the targeting dual-responsive supramolecular vesicles (CAAP5G) based on the CAAP5 and G host-guest interaction, an aqueous solution of CAAP5 and G was sonicated for 30 min. We observed a clear Tyndall effect (Figure 1A right), indicating the existence of abundant nanoparticles, which were further identified by scanning electron microscopy SEM (Figure 1B). TEM image demonstrated the cavity of the vesicles, which was used to loading-drug (Figure 1C). Further analysis with DLS showed that the average diameter of the vesicles was 158 nm (Figure 1D). The critical aggregation concentration (CAC) was found to be 22 µM by the water surface tension method (Figure S14).

In the following study, DOX was selected as a model drug to investigate the drug release behavior and encapsulation efficiency of the supramolecular vesicles. As showed in Figure 1A (left), a clear Tyndall effect was observed with DOX-loaded CAAP5G aqueous solution. DLS showed that the average diameter of the DOX-loaded CAAP5G vesicles was 203 nm (Figure S13), which were further identified by SEM (Figure 2A). The CAAP5G encapsulation efficiency was calculated 41 wt% by UV-vis spectroscopy. Subsequently, the DOX-loaded CAAP5G vesicles released DOX was studied in an acidic solution (pH 4.0), neutral solution (pH 7.4), and with GSH

Figure 1 (A) Tyndall effect of CAAP5G and DOX-loaded CAAP5G; (B) SEM image of CAAP5G vesicles; (C) TEM image of CAAP5G vesicles; (D) DLS histogram of CAAP5G vesicles.
(10 mM) in solution (pH 7.0) and acidic solution (pH 4.0), respectively, mimicking the concentration of GSH in cancer cells (1–11 mM). As indicated in Figure 2B, 20% and 54% of DOX were released under acidic conditions (pH 4.0) and 10 mM GSH, respectively. In the acidic buffer solutions, CAAP5 functional groups -NH$_2$ were ionized to -NH$_3^+$, leading to a greater quantity of positive charges, which changed the CAAP5 hydrophilic/hydrophobic ratio and further lead to the rupture of vesicles to release drugs. As a result, the solution in the presence of GSH had a quicker release rate. By comparison, the amount of DOX release reached a maximum of 62% when cultured with GSH (10 mM) in solution (pH 4.0), indicating that GSH and pH dual-responsiveness mediated efficient disassembly of DOX-loaded vesicles. These results show that DOX-loaded CAAP5G vesicles are relative stable under physiological condition and can be used for drug controllable release.

The cellular uptake of DOX-loaded vesicles was investigated by CLSM. Red fluorescence could be observed clearly in the nuclei of HepG2 cells after 4 h incubation with DOX-loaded CAAP5G vesicles, indicating that DOX loaded by CAAP5G vesicles could enter the cancer cells (Figure 3A). To evaluate the targeting effect of CAAP5G vesicles, HepG2
cells were incubated with DOX-loaded CAAP5G vesicles and free DOX at 5 µM for 4 h, respectively, where the efficiency of cellular uptake was analyzed by flow cytometry. HepG2 cells pre-cultured with lactose (2 mg/mL) for 4 h, were used to culture with DOX-loaded CAAP5G vesicles for comparison. As showed in Figure 3B, the fluorescence intensity of HepG2 cells cultured with DOX-loaded CAAP5G vesicles (blue curve) was higher than that of DOX-loaded CAAP5G with lactose pre-incubation (green curve), indicating a higher uptake of DOX-loaded CAAP5G vesicles. The results imply that CAAP5G displays hepatoma-targeting ability. In addition, the cell toxicity of unloaded vesicles to 293T cells are evaluated by the MTT cell survival assay. As indicated in Figure S15 (ESI†), the relative cell viability of 293T cells cultured with unloaded vesicles was over 82% in the concentrations of 50 µM CAAP5G after 24 h, showing that the vesicles had low cell toxicity to 293T cells, which was essential for the design of drug nano-carriers.

The anticancer efficiency of DOX-loaded CAAP5G vesicles was evaluated using MTT cell survival assay, where HepG2 cells and 293T cells were incubated with free DOX and DOX-loaded CAAP5G vesicles for 24, 48, and 72 h, respectively. As indicated in Figure 4A, in all three tested periods, the relative viabilities of HepG2 cells after cultured with DOX-loaded CAAP5G vesicles were visibly lower than those with free DOX. By comparison, 293T cells showed higher relative viabilities than those with free DOX (Figure 4A). The results indicated that the encapsulation of DOX by CAAP5G vesicles could enhance the drug anticancer efficiency for HepG2 cells while effectively reduce the side effects to 293T cells.

In the presence of GSH, CAAP5G vesicles can produce the cysteamine, an adjuvant chemotherapy drug, that enhances the cytotoxicity of DOX.42 To study the adjuvant chemotherapy efficiency of CAAP5G vesicles, HepG2-ADR cells were cultured with free DOX and DOX-loaded CAAP5G vesicles for 24, 48, and 72 h, respectively (Figure 5). The results showed that the relative viabilities of HepG2-ADR cells after incubation with DOX-loaded CAAP5G vesicles at all three tested time periods were visibly lower than those with free DOX. It indicated DOX-loaded CAAP5G vesicles could enhance anticancer efficiency of HepG2-ADR cells comparison with free DOX, suggesting CAAP5G as a multifunctional supramolecular vesicle can be used in adjuvant chemotherapy.

**Conclusion**

In conclusion, novel multifunctional supramolecular vesicles (CAAP5G) based on the host-guest complexation of CAAP5 and G have been successfully constructed and the good drug-loading capability was demonstrated by drug loading experiments. Furthermore, DOX-loaded CAAP5G not only exhibited excellent dual stimuli responsiveness and rapid release of DOX in cancer cells but also possesses targeting ability to ASGP-R overexpressing HepG2 cells. Most notably, the vesicles under high concentration of GSH would release cysteamine, which could enhance the anticancer efficiency of DOX and reduce the drug resistance of cancer cells. This work provides a new idea for rational design in the construction of targeted and stimuli-responsive nanocarriers for drug delivery, which have great applications for adjuvant chemotherapy.

![Figure 4](https://www.dovepress.com/)

**Figure 4** Comparison of DOX-loaded CAAP5G vesicles and DOX on viabilities of HepG2 cells (A) and 293T cells (B) at different time periods; the concentration of DOX was 5 µM. Statistically significant differences were observed (*p<0.05).
Cancers 2013;52:7487

Figure 5 Comparison of DOX-loaded CAAPSG vesicles and DOX on viabilities of HepG2-ADR cells at different time periods; the concentration of DOX was 5 µM. Statistically significant differences were observed (*p<0.05).

Acknowledgments
This research work was supported by the National Natural Science Foundation of China (No. 21572181 and 21772517), Specialized Research Fund for the Doctoral Program of Hebei Agricultural University (2D201712), and Science & Technology Fund of Hebei Agricultural University (LG201811).

Disclosure
The authors report no conflicts of interest in this work.

References
1. Mousa SA, Bharali DJ. Nanotechnology-based detection and targeted therapy in cancer: nano-bioparadigms and applications. Cancers 2011;3:2888–2903. doi:10.3390/cancers3032888
2. Shao C, Shang K, Xu HB, et al. Facile fabrication of hypericin-entrapped glyconanoparticles for targeted photodynamic therapy. Int J Nanomedicine 2018;13:4319–4331. doi:10.2147/IJN.S161262
3. Liu J, Huang YR, Kumar A, et al. pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv 2014;32:693–710. doi:10.1016/j.biotechadv.2013.11.009
4. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818–1822. doi:10.1126/science.1095833
5. Zhao ZL, Meng HM, Wang NN, et al. A controlled-release nanocarrier with extracellular pH value driven tumor targeting and translocation for drug delivery. Angew Chem Int Ed 2013;52:7487–7491. doi:10.1002/anie.201302557
6. Wang ZH, Tian YF, Zhang H, et al. Using hyaluronic acid-functionalized pH stimuli-responsive mesoporous silica nanoparticles for targeted delivery to CD44-overexpressing cancer cells. Int J Nanomedicine 2016;11:6485–6497. doi:10.2147/IJN.S117184
7. Cao SP, Pei ZC, Xu YQ, Pei YX. Glyco-nanovesicles with activatable near-Infrared probes for real-time monitoring of drug release and targeted delivery. Chem Mater 2016;28:4501–4506. doi:10.1021/acs.chemmater.6b01857
8. Kanamala M, Wilson WR, Yang M, Palmer BD, Wu Z. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review. Biomaterials 2015;36:152–167. doi:10.1016/j.biomaterials.2014.05.061
9. Zhang Y, Wu XW, Hou CX, et al. Dual-responsive dithio-polydopamine coated porous CeO2 nanorods for targeted and synergistic drug delivery. Int J Nanomedicine 2018;13:2161–2173. doi:10.2147/IJN.S152002
10. Feng QH, Zhang YY, Zhang WX, et al. Tumor-targeted and multi-stimuli responsive drug delivery system for near-infrared light induced chemo-phototherapy and photoacoustic tomography. Acta Biomater 2016;38:129–142. doi:10.1016/j.actbio.2016.04.024
11. Cui W, Li J, Decher G. Self-assembled smart nanocarriers for targeted drug delivery. Adv Mater 2016;28:1302–1311. doi:10.1002/adma.201502479
12. Dai LL, Liu JJ, Luo Z, Li M, Cai KY. Tumor therapy: targeted drug delivery systems. J Mater Chem B 2014;2:4675–4672. doi:10.1039/C4TB01743F
13. Liu CQ, Chen ZW, Wang ZZ, et al. A graphite hollow carbon nitride nanoparticle as a novel photochemical internalization agent for targeted and stimuli-responsive cancer therapy. Nanoscale 2016;8:12570–12578. doi:10.1039/C5nr07719b
14. Meng LB, Zhang WY, Li DQ, et al. pH-responsive supramolecular vesicles assembled by water-soluble pillar[5]arene and a BODIPY photosensitizer for chemo-photodynamic dual therapy. Chem Commun 2015;51:14381–14384. doi:10.1039/C5CC05785J
15. Gao LY, Zheng B, Chen W, Schalley CA. Enzyme-responsive pillar[5]arene-based polymer-substituted amphiphiles: synthesis, self-assembly in water, and application in controlled drug release. Chem Commun 2015;51:14901–14904. doi:10.1039/C5CC06207A
16. Chang YC, Yang K, Wei P, et al. Cationic vesicles based on amphiphilic pillar[5]arene capped with ferrocenium: a redox-responsive system for drug/siRNA co-delivery. Angew Chem Int Ed 2014;53:13126–13130. doi:10.1002/anie.201407272
17. Yu GC, Han CY, Zhang ZB, et al. Pillar[6]arene-based photosensitive host-guest complexation. J Am Chem Soc 2012;134:8711–8717. doi:10.1021/ja302998q
18. Lee BS, Yip AT, Thach AV, Rodriguez AR, Deming TJ, Kamei DT. The targeted delivery of doxorubicin with transferrin-conjugated block copolymer vesicles. Int J Pham 2015;496:903–911. doi:10.1016/j.ijpharm.2015.10.028
19. Chi XD, Yu GC, Shao L, Chen JZ, Huang FH. A dual-thermosresponsive gemini-type supra-amphiphilic macromolecular [3] pseudorotaxane based on pillar[10]arene/paraquat cooperative complexation. J Am Chem Soc. 2016;138:3168–3174. doi:10.1021/jacs.5b13173

20. Duan QP, Yao Y, Li Y, et al. pH-responsive supramolecular vesicles based on water-soluble pillar[5]arene and ferrocene derivative for drug delivery. J Am Chem Soc. 2013;135:10542–10549. doi:10.1021/ja405014r

21. Ogoshi T, Kanai S, Fujinami S, Yamagishi TA, Nakamoto Y. Para-Bridged symmetrical pillar[5]arenes: their Lewis acid catalyzed synthesis and host-guest property. J Am Chem Soc. 2008;130:5022–5023. doi:10.1021/ja711620m

22. Li H, Chen DX, Sun YL, et al. Viologen-mediated assembly of and sensing with carboxylatopillar[5]arene-modified gold nanoparticles. J Am Chem Soc. 2013;135:1570–1576. doi:10.1021/ja3115168

23. Chen L, Si W, Zhang L, Li G, Li Z-H, Hou J-L. Chiral selective transmembrane transport of amino acids through artificial channels. J Am Chem Soc. 2013;135:2125–2155. doi:10.1021/ja312704e

24. Yu GC, Jie KC, Huang FH. Supramolecular amphiphiles based on host-guest molecular recognition motifs. Chem Rev. 2015;115:7240–7303. doi:10.1021/cm5005515

25. Wang YL, Ping GC, Li CJ. Efficient complexation between pillar[5]arenes and neutral guests: from host-guest chemistry to functional materials. Chem Commun. 2016;52:9858–9872. doi:10.1039/C6CC0399E

26. Xiao TX, Zhong WW, Zhou L, et al. Artificial light-harvesting systems fabricated by supramolecular host–guest interactions. Chin Chem Lett. 2019;30:31–36. doi:10.1016/j.ccl.2018.05.034

27. Xu HB, Chen L, Si W, Yu YH, Hou JL. Pillar[5]arene decahene: synthesis, encapsulation of very long linear diacids and formation of ion pair-stopped [2]rotaxanes. Chem Commun. 2011;47:4694–4696. doi:10.1039/C1CC10337G

28. Wang Y, Xu JF, Chen YZ, et al. Photosensitive supramolecular self-assembly of monofunctionalized pillar[5]arene based on stiff stilbene. Chem Commun. 2014;50:7001–7003. doi:10.1039/C4CC02760D

29. Chi XD, Ji XF, Xia DY, Huang FH. A dual-responsive supra-amphiphilic poly(pseudorotaxane constructed from a water-soluble pillar[7]arene and an azobenzene-containing random copolymer. J Am Chem Soc. 2015;137:1440–1443. doi:10.1021/ja512978n

30. Yang K, Pei YY, Wen J, Pei ZC. Recent advances in pillar[n]arenes: synthesis and applications based on host-guest interactions. Chem Commun. 2016;52:9316–9326. doi:10.1039/C6CC0641D

31. Jiang L, Huang X, Chen D, Yan H, Li X, Du X. Supramolecular vesicles coassembled from disulfide-linked benzimidazolium amphiphiles and carbobamate-substituted pillar[6]arenes that are responsive to five stimuli. Angew Chem Int Ed. 2017;56:2655–2659. doi:10.1002/anie.201611973

32. Yang K, Chang YC, Wen J, et al. Supramolecular vesicles based on complex of trp-modified pillar[5]arene and galactose derivative for synergistic and targeted drug delivery. Chem Mater. 2016;28:1990–1993. doi:10.1021/acs.chem Mater.6b00696

33. Chang YC, Hou CX, Ren JL, et al. Multifunctional supramolecular vesicles based on the complex of ferrocenecarboxylic acid capped pillar[5]arene and a galactose derivative for targeted drug delivery. Chem Commun. 2016;52:9578–9581. doi:10.1039/C6CC03637F

34. Hasan W, Beuzard Y, Rosa J. Inhibition of erythrocyte sickling by cystamine, a thiol reagent. Proc Natl Acad Sci U S A. 1976;73:3288–3292.

35. Alemán MM, Holle LA, Stember KG, et al. Cystamine preparations exhibit anticoagulant activity. PLoS One. 2015;10:e0124448. doi:10.1371/journal.pone.0124448

36. Karpju MV, Becher MW, Springer JE, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med. 2002;8:143–149. doi:10.1038/nm0202-143

37. Besoum M, Masereeuw R, Heuvel LVD, Levchenko E. Cysteamine: an old drug with new potential. Drug Discov Today. 2013;18:785–792. doi:10.1016/j.drudis.2013.02.003

38. Ianno H, Onoda M, Suzuki K, Kobayashi H, Wakabayashi K. Inhibitory effects of WR-2721 and cysteamine on tumor initiation in mammary glands of pregnant rats by radiation. Radiat Res. 2000;153:68–74. doi:10.1667/0033-7587(2000)153<0068:eworc2>0.2.co2

39. Tatsuta M, Ishi H, Yamamura H, Baba M, Mikuni T, Taniguchi H. Inhibitory effect of prolonged administration of cysteamine on experimental carcinogenesis in rat stomach induced by N-methyl-N’-nitro-N-nitrosoguanidine. Int J Cancer. 1998;41:423–426.

40. Fujisawa T, Rubin B, Suzuki A, et al. Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer. PLoS One. 2012;7:e34437. doi:10.1371/journal.pone.0034437

41. Lespinasse F, Oiry J, Fatome M, et al. Radioprotection of EMT6 tumor by a new class of radioprotectors based on a pseudo-peptide cysteamine combination. Int J Radiat Oncol Biol Phys. 1985;11:1035–1038.

42. Wan XM, Zheng F, Zhang L, et al. Autophagy-mediated chemosensitization by cysteamine in cancer cells. Int J Cancer. 2011;129:1087–1095. doi:10.1002/ijic.25771

43. Chen W, Zou Y, Meng F, et al. Glyco-nanoparticles with sheddable saccharide shells: a unique and potent platform for hepatoma-targeting delivery of anticancer drugs. Biomacromolecules. 2014;15:900–907. doi:10.1021/bm401749f

44. Chang YC, Ly VH, Wei P, et al. Multifunctional glycol-nanofibers: siRNA induced supramolecular assembly for codelivery. Adv Funct Mater. 2017;27:1703083. doi:10.1002/adfm.201703083

45. Zhang J, Li C, Wang Y, Zhou RX, Zhang XZ. Controllable exploding microcapsules as drug carriers. Chem Commun. 2011;47:4457–4459. doi:10.1039/c1cc10337g

46. Yang J, Shao L, Yu GC. Construction of pillar[n]arene-based CO2 and UV dual-responsive supra-amphiphile and application in controlled self-assembly. Chem Commun. 2016;52:3211–3214. doi:10.1039/C5CC0617F